Patient-Derived Organoids as a Model for Cancer Drug Discovery
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
In the search for the ideal model of tumours, the use of three-dimensional in vitro models is advancing rapidly. These are intended to mimic the in vivo properties of the tumours which affect cancer development, progression and drug sensitivity, and take into account cell–cell interactions, adhesion and invasiveness. Importantly, it is hoped that successful recapitulation of the structure and function of the tissue will predict patient response, permitting the development of personalized therapy in a timely manner applicable to the clinic. Furthermore, the use of co-culture systems will allow the role of the tumour microenvironment and tissue–tissue interactions to be taken into account and should lead to more accurate predictions of tumour development and responses to drugs. In this review, the relative merits and limitations of patient-derived organoids will be discussed compared to other in vitro and ex vivo cancer models. We will focus on their use as models for drug testing and personalized therapy and how these may be improved. Developments in technology will also be considered, including the use of microfluidics, 3D bioprinting, cryopreservation and circulating tumour cell-derived organoids. These have the potential to enhance the consistency, accessibility and availability of these models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“Importantly, the characteristics of the tumours should also be maintained in the organoids at different passages, and this has been demonstrated in organoids derived from colorectal and gastric cancer [3,5,6].”
BackgroundSelf-citationA living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis
Takasato, M., Er, P. X., Chiu, H. S., Maier, B., Baillie, G. J., Ferguson, C., Parton, R. G., Wolvetang, E. J., Roost, M. S., Chuva de Sousa Lopes, S. M., et al. (2015) · Nature · doi:10.1038/nature15695 · Cited by 1,627
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Organoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
Three-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Progress and potential in organoid research
Rossi, G., Manfrin, A., & Lutolf, M. P. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0051-9 · Cited by 1,182 · cited 5×
“The interaction of cancer cells with components of the tissue microenvironment was also effectively evaluated in a study by Montanez-Sauri et al., where breast carcinoma cells were co-cultured with fibroblasts and combinations of different ECM proteins [98].”
BackgroundInfluentialDijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135 · cited 1×
“Interestingly, this approach has also been utilized to generate patient-specific tumour-reactive T cells from peripheral blood lymphocytes [66], allowing the interrogation of tumour sensitivity to immunotherapy.”
MethodOrganoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092
Cancer modeling meets human organoid technology
Tuveson, D., & Clevers, H. (2019) · Science · doi:10.1126/science.aaw6985 · Cited by 935 · cited 1×
“It is anticipated that these organoids (patient-derived organoids, PDO) will contribute to the approaches of short-term culture and xenotransplantation [7].”
BackgroundModelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906 · cited 4×
“By growing organoids in chips lined by normal non-tumour cells, these devices can be used to model tumour progression, expansion, invasion and metastasis [86,99].”
BackgroundInfluentialTumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
Park, S. E., Georgescu, A., & Huh, D. (2019) · Science · doi:10.1126/science.aaw7894 · Cited by 847
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812 · cited 3×
“Similarly, sensitivity to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor drug Erlotinib correlated with EGFR-mutations in lung cancer-derived organoids [29].”
BackgroundPatient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., Pan, M., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.10.010 · Cited by 755
Tumor-associated stromal cells as key contributors to the tumor microenvironment
Bussard, K. M., Mutkus, L., Stumpf, K., Gomez-Manzano, C., & Marini, F. C. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0740-2 · Cited by 746 · cited 1×
“These cells include mesenchymal cells, fibroblasts, endothelial cells, adipocytes and immune cells, which secrete a variety of soluble factors, such as pro-inflammatory cytokines, matrix metalloproteinases and growth factors [62].”
BackgroundYan, H. H. N., Siu, H. C., Law, S., Ho, S. L., Yue, S. S. K., Tsui, W. Y., Chan, D., Chan, A. S., Ma, S., Lam, K. O., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.09.016 · Cited by 724
A rectal cancer organoid platform to study individual responses to chemoradiation
Ganesh, K., Wu, C., O’Rourke, K. P., Szeglin, B. C., Zheng, Y., Sauvé, C.-E. G., Adileh, M., Wasserman, I., Marco, M. R., Kim, A. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0584-2 · Cited by 569
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0474 · Cited by 452
3D microtumors in vitro supported by perfused vascular networks
Sobrino, A., Phan, D. T. T., Datta, R., Wang, X., Hachey, S. J., Romero-López, M., Gratton, E., Lee, A. P., George, S. C., & Hughes, C. C. W. (2016) · Scientific Reports · doi:10.1038/srep31589 · Cited by 387 · cited 1×
“Another microfluidic platform with vascularized microtumours was used to distinguish between drugs which were effective in disrupting vascular networks [94].”
MethodA Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341 · cited 1×
“Interestingly, given the frequency of p53 mutations in cancers, a drug which rescues p53 function (ReACp53) induced apoptosis in organoids with mutations in p53 [44].”
BackgroundMicrofluidic Endothelium for Studying the Intravascular Adhesion of Metastatic Breast Cancer Cells
Song, J. W., Cavnar, S. P., Walker, A. C., Luker, K. E., Gupta, M., Tung, Y.-C., Luker, G. D., & Takayama, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005756 · Cited by 317 · cited 1×
“These systems have been used to provide an insight into the interaction between circulating tumour cells and the vasculature by demonstrating the promotion of adherence of these cells to endothelium by chemokine CXCL12 [97].”
Shirure, V. S., Bi, Y., Curtis, M. B., Lezia, A., Goedegebuure, M. M., Goedegebuure, S. P., Aft, R., Fields, R. C., & George, S. C. (2018) · Lab on a Chip · doi:10.1039/c8lc00596f · Cited by 316 · cited 1×
“tissue through a perfusable blood vessel network [93].”
BackgroundXu, Z., Gao, Y., Hao, Y., Li, E., Wang, Y., Zhang, J., Wang, W., Gao, Z., & Wang, Q. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.045 · Cited by 295
Phan, N., Hong, J. J., Tofig, B., Mapua, M., Elashoff, D., Moatamed, N. A., Huang, J., Memarzadeh, S., Damoiseaux, R., & Soragni, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0305-x · Cited by 269 · cited 3×
“Crucially, the drug sensitivities observed using this method appeared to correlate to patient responses [84].”
BackgroundMethodInfluentialZhou, T., Tan, L., Cederquist, G. Y., Fan, Y., Hartley, B. J., Mukherjee, S., Tomishima, M., Brennand, K. J., Zhang, Q., Schwartz, R. E., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.06.017 · Cited by 263 · cited 1×
“Drug screening, however, is not limited to cancer therapies, and organoids have also been used successfully to screen drugs for a variety of other diseases, including cystic fibrosis [33] and Zika virus infection [34], further indicating the usefulness of these models.”
BackgroundWang, Y., Wang, H., Deng, P., Chen, W., Guo, Y., Tao, T., & Qin, J. (2018) · Lab on a Chip · doi:10.1039/c8lc00869h · Cited by 222 · cited 1×
“This has previously been demonstrated using brain and liver organoids [92,95], and apoptosis induction has been measured in organoids from small-cell lung tumours in response to the chemotherapeutic agents cisplatin and etoposide [96].”
BackgroundKhoo, B. L., Grenci, G., Lim, Y. B., Lee, S. C., Han, J., & Lim, C. T. (2018) · Nature Protocols · doi:10.1038/nprot.2017.125 · Cited by 172
Nanki, Y., Chiyoda, T., Hirasawa, A., Ookubo, A., Itoh, M., Ueno, M., Akahane, T., Kameyama, K., Yamagami, W., Kataoka, F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69488-9 · Cited by 165 · cited 1×
“Organoids derived from ovarian cancers harbouring mutations in BRCA1 also predicted their sensitivity to platinum drugs, paclitaxel and PARP inhibitors, in comparison to organoids derived from clear cell ovarian cancer, which were resistant to conventional therapies [43].”
Precision-cut liver slices: a versatile tool to advance liver research
Palma, E., Doornebal, E. J., & Chokshi, S. (2019) · Hepatology International · doi:10.1007/s12072-018-9913-7 · Cited by 125
Precision-cut human liver slice cultures as an immunological platform
Wu, X., Roberto, J. B., Knupp, A., Kenerson, H. L., Truong, C. D., Yuen, S. Y., Brempelis, K. J., Tuefferd, M., Chen, A., Horton, H., et al. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.01.012 · Cited by 81 · cited 1×
“However, it has been suggested that the gene expression profiles of these slices, and their response to exogenous stimuli, could be maintained in ex vivo culture for up to 15 days [79], demonstrating that they may have potential applications for drug screening.”
BackgroundBoussaad, I., Cruciani, G., Bolognin, S., Antony, P., Dording, C. M., Kwon, Y.-J., Heutink, P., Fava, E., Schwamborn, J. C., & Krüger, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-81129-3 · Cited by 42 · cited 1×
“An automated platform for the high-throughput screening of patient-derived 3D organoids has recently been described; however, this system was not able to use organoids embedded in the extracellular matrix [82].”
MethodImplementing biological markers as a tool to guide clinical care of patients with pancreatic cancer
Iovanna, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.100965 · Cited by 18 · cited 1×
“Liquid biopsies, particularly blood samples, are non-invasive and may be utilized to detect potential biomarkers, such as circulating tumour cells, methylated DNA, cell free DNA, circulating RNA (including microRNA) and extracellular vesicles (including exosomes) [52,53].”
Background
Cited by
3D and organoid culture in research: physiology, hereditary genetic diseases and cancer
Suarez-Martinez, E., Suazo-Sanchez, I., Celis-Romero, M., & Carnero, A. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00775-w · Cited by 118
Allgayer, H., Mahapatra, S., Mishra, B., Swain, B., Saha, S., Khanra, S., Kumari, K., Panda, V. K., Malhotra, D., Patil, N. S., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02338-2 · Cited by 127
Yang, M., Li, S., Li, R., Dong, Y., Zhou, M., Zhao, J., Liu, M., & Tan, R. (2026) · New Biotechnology · doi:10.1016/j.nbt.2026.05.006
Yang, M., Li, R., Dong, Y., Zhou, M., Zhao, J., Liu, M., & Tan, R. (2026) · doi:10.64898/2026.01.28.702456
“Organoids also support personalized treatment by predicting patient-specific drug responses, helping to identify the most effective therapies and streamline drug discovery[12].”
Metadata
- Authors
- Rae, C., Amato, F., & Braconi, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-03-27
- Volume
- 22
- Issue
- 7
- Pages
- 3483
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3142728032
- Cited by
- 62
- References
- 36
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.